Shelby Derene Reed, PhD

Professor in Population Health Sciences
Professor in Medicine
Associate of the Duke Initiative for Science & Society
Executive Core Faculty Member, Duke-Margolis Center for Health Policy
Member in the Duke Clinical Research Institute
Member of the Duke Cancer Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8991
Email address shelby.reed@duke.edu

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018.

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018. she is currently Chair of ISPOR's Health Science Policy Council.

 

Areas of expertise: Health Economics, Health Measurement, Stated Preference Research, Health Policy, and Health Services Research

Education and Training

  • Ph.D., University of Maryland, College Park, 1998

Publications

Fairchild, A. O., E. G. Katz, S. D. Reed, F. R. Johnson, A. DiBernardo, D. Hough, J. Sing, and B. Levitan. “Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel.” Neurology Psychiatry and Brain Research 37 (September 1, 2020): 67–78. https://doi.org/10.1016/j.npbr.2020.05.003.

Full Text

Bhatt, Deepak L., Andrew H. Briggs, Shelby D. Reed, Lieven Annemans, Michael Szarek, Vera A. Bittner, Rafael Diaz, et al. “Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.” J Am Coll Cardiol 75, no. 18 (May 12, 2020): 2297–2308. https://doi.org/10.1016/j.jacc.2020.03.029.

PMID
32381160
Full Text

Ahmadi, Sara, Juan Marcos Gonzalez, Maya Talbott, Shelby D. Reed, Jui-Chen Yang, Randall P. Scheri, Michael Stang, Sanziana Roman, and Julie Ann Sosa. “Patient Preferences Around Extent of Surgery in Low-Risk Thyroid Cancer: A Discrete Choice Experiment.” Thyroid, April 15, 2020. https://doi.org/10.1089/thy.2019.0590.

PMID
32143553
Full Text

Lim, Stephanie L., Jui-Chen Yang, Jessie Ehrisman, Laura J. Havrilesky, and Shelby D. Reed. “Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?” Patient, April 2, 2020. https://doi.org/10.1007/s40271-020-00416-9.

PMID
32239442
Full Text

Bhatt, Ankeet S., Andrew P. Ambrosy, Allison Dunning, Adam D. DeVore, Javed Butler, Shelby Reed, Adriaan Voors, et al. “The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.” Eur J Heart Fail, March 25, 2020. https://doi.org/10.1002/ejhf.1795.

PMID
32212297
Full Text

Saullo, Jennifer L., Yanhong Li, Julia A. Messina, Jillian Thompson, Tara Dalton, Vinay K. Giri, Shelby D. Reed, et al. “Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.” Biol Blood Marrow Transplant 26, no. 3 (March 2020): 568–80. https://doi.org/10.1016/j.bbmt.2019.11.005.

PMID
31712193
Full Text

Havrilesky, Laura J., Stephanie Lim, Jessie A. Ehrisman, Amelia Lorenzo, Angeles Alvarez Secord, Jui-Chen Yang, F Reed Johnson, Juan Marcos Gonzalez, and Shelby D. Reed. “Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.” Gynecol Oncol 156, no. 3 (March 2020): 561–67. https://doi.org/10.1016/j.ygyno.2020.01.026.

PMID
31982178
Full Text

Reed, Shelby D., and Lori McLeod. “Moving Beyond the Tip of the Iceberg to Incorporate Patients' Perspectives and Outcomes in the Medical Device Regulatory Process.” Value Health 23, no. 3 (March 2020): 298–99. https://doi.org/10.1016/j.jval.2020.01.008.

PMID
32197724
Full Text

Bewtra, Meenakshi, Shelby D. Reed, F Reed Johnson, Frank I. Scott, Erin Gilroy, Robert S. Sandler, Wenli Chen, and James D. Lewis. “Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents.” Clin Gastroenterol Hepatol 18, no. 2 (February 2020): 406-414.e7. https://doi.org/10.1016/j.cgh.2019.05.010.

PMID
31100456
Full Text

Reed, Shelby D., Yanhong Li, Helen A. Dakin, Frauke Becker, Jose Leal, Stephanie M. Gustavson, Bernt Kartman, et al. “Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).” Diabetes Care 43, no. 2 (February 2020): 374–81. https://doi.org/10.2337/dc19-0950.

PMID
31806653
Full Text

Pages